{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:59:46Z","timestamp":1787021986023,"version":"build-2736575974"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanfilippo Children's Research Foundation (Canada)"},{"name":"Sanfilippo Chilrens's Research Foundation (Canada)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162145","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T13:43:06Z","timestamp":1474551786000},"page":"e0162145","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["NDST1 Preferred Promoter Confirmation and Identification of Corresponding Transcriptional Inhibitors as Substrate Reduction Agents for Multiple Mucopolysaccharidosis Disorders"],"prefix":"10.1371","volume":"11","author":[{"given":"Ilona","family":"Tkachyova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"LamHonWah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdana","family":"Fedyshyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Tein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don J.","family":"Mahuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-1095","authenticated-orcid":true,"given":"Andreas","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/B978-0-444-59565-2.00042-3","article-title":"Mucopolysaccharidoses and mucolipidoses","volume":"113","author":"JE Wraith","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of Hurler syndrome after stem cell transplantation","volume":"14","author":"M Aldenhoven","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 5","key":"ref3","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","article-title":"Therapy for the mucopolysaccharidoses","volume":"50","author":"V Valayannopoulos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"ref4","first-page":"S63","article-title":"Enzyme replacement therapy for the management of the mucopolysaccharidoses","volume":"47","author":"JE Wraith","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders","volume":"23","author":"G Parenti","year":"2015","journal-title":"Mol Ther"},{"issue":"9","key":"ref6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"LL Bennett","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease","volume":"9","author":"LL Bennett","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nbd.2004.05.002","article-title":"Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C","volume":"16","author":"RH Lachmann","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"41","key":"ref9","doi-asserted-by":"crossref","first-page":"42355","DOI":"10.1074\/jbc.C400373200","article-title":"Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains no N-sulfate groups","volume":"279","author":"K Holmborn","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1042\/bst0310340","article-title":"Glucosaminyl N-deacetylase\/N-sulphotransferases in heparan sulphate biosynthesis and biology","volume":"31","author":"L Kjellen","year":"2003","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1074\/jbc.M009606200","article-title":"Multiple isozymes of heparan sulfate\/heparin GlcNAc N-deacetylase\/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4","volume":"276","author":"J Aikawa","year":"2001","journal-title":"J Biol Chem"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/glycob\/cwf072","article-title":"Variant heparan sulfates synthesized in developing mouse brain differentially regulate FGF signaling","volume":"12","author":"M Ford-Perriss","year":"2002","journal-title":"Glycobiology"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2567.2008.02856.x","article-title":"Small changes in lymphocyte development and activation in mice through tissue-specific alteration of heparan sulphate","volume":"125","author":"OB Garner","year":"2008","journal-title":"Immunology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13059-014-0560-6","article-title":"Gateways to the FANTOM5 promoter level mammalian expression atlas","volume":"16","author":"M Lizio","year":"2015","journal-title":"Genome Biol"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1101\/gr.229102. Article published online before print in May 2002","article-title":"The human genome browser at UCSC","volume":"12","author":"WJ Kent","year":"2002","journal-title":"Genome Res"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"GH Maegawa","year":"2007","journal-title":"J Biol Chem"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.chembiol.2012.07.015","article-title":"Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter","volume":"19","author":"N Thorne","year":"2012","journal-title":"Chem Biol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1073\/pnas.64.1.360","article-title":"The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation","volume":"64","author":"JC Fratantoni","year":"1969","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11011-010-9230-x","article-title":"Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice","volume":"26","author":"DM McCarty","year":"2011","journal-title":"Metab Brain Dis"},{"issue":"43","key":"ref20","doi-asserted-by":"crossref","first-page":"37515","DOI":"10.1074\/jbc.M111.287474","article-title":"Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking alpha-l-iduronidase","volume":"286","author":"RJ Holley","year":"2011","journal-title":"J Biol Chem"},{"issue":"43","key":"ref21","doi-asserted-by":"crossref","first-page":"36283","DOI":"10.1074\/jbc.M112.403360","article-title":"A genetic model of substrate reduction therapy for mucopolysaccharidosis","volume":"287","author":"WC Lamanna","year":"2012","journal-title":"J Biol Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:21:53Z","timestamp":1540336913000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162145"}},"subtitle":[],"editor":[{"given":"Chunhong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162145","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]}}}